PFCD Statement on Mandatory Medicare Demos Implementing Most Favored Nation Drug Pricing

December 19, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D:

“PFCD remains opposed to a MFN approach to drug price-setting that would import foreign price controls, threaten patient access, pose ethical concerns, stifle U.S. medical innovation, and adopt discriminatory metrics of value, despite federal law prohibiting the use of such metrics in Medicare. The nearly one in three Americans living with two or more chronic conditions rely on timely access to needed therapies. By tying prices to external benchmarks, these MFN models threaten to reduce the availability of key therapies, create sudden shifts in medical coverage, and introduce uncertainty that disrupts long-standing care routines. These effects are especially concerning for individuals who depend on consistent, long-term treatment plans to manage complex conditions.

“While such policies claim to be aimed at lowering costs, they ultimately hinder patient-centered care and outcomes for the 130 million Americans with multiple chronic conditions by limiting therapeutic options and delaying access to treatments and care. Instead, policymakers should keep patient access and outcomes at the core of any solutions and focus instead on reining in pharmacy benefit managers and demanding greater transparency around rising premiums, deductibles, and coinsurance.

“No matter how appealing the promise, it is not possible to impose foreign price controls and continue to maintain U.S. leadership in innovation and patient access to cutting-edge medical advances.”